UBS Upgrades Teva Pharmaceutical Indus to Buy, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma upgraded Teva Pharmaceutical Industries (NYSE:TEVA) from Neutral to Buy and increased the price target from $11 to $13.

November 27, 2023 | 10:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS upgraded Teva Pharmaceutical Industries to Buy from Neutral and raised the price target to $13 from $11.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved fundamentals or better future prospects for the company. The increase in price target further reinforces the positive outlook, likely leading to increased investor confidence and potential share price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100